Fig. 3From: Effect of an enteral amino acid blend on muscle and gut functionality in critically ill patients: a proof-of-concept randomized controlled trialPlasma I-FABP (pg/mL) in the amino acid and placebo groups. Plasma I-FABP was assessed by ELISA. Values reported are mean changes from baseline at days 7, 14, 21 and 60, using a restricted maximum likelihood (REML)-based repeated measures approachBack to article page